CrossrefInfokarte
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma
ONCOLOGY · 2023-04-12 · (3704) · 176-183
DOI: 10.46883/2023.25920992 ↗Abstract
Kein Abstract verfügbar.
EUVIMED